advertising
-
1
Harrington C, Zagari MJ, Corea J, et al: A cost analysis of diabetic lower-extremity ulcers. .Diabetes Care 23::1333. ,2000. .
-
2
Hogan P, Dall T, Nikolov P: Economic costs of diabetes in the US in 2002. .Diabetes Care 26::917. ,2003. .
-
3
Gordois A, Scuffham P, Shearer A, et al: The health care costs of peripheral neuropathy for people with diabetes in the U.S. .Diabetes Care 26::1790. ,2003. .
-
4
Shearer A, Gordois A, Scuffham P, et al: Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. .Diabetes Care 26::2305. ,2003. .
-
5
US Department of Health and Human Services: Healthy People 2010, 2nd Ed, US Government Printing Office, Washington, DC, November. 2000. .
-
6
Centers for Medicare and Medicaid Services: Decision Memorandum for Diabetic Peripheral Neuropathy with Loss of Protective Sensation (LOPS) (CAG-00059), Centers for Medicare and Medicaid Services, Baltimore, October. 2001. .
-
7
Bild DE, Selby JV, Sinnock JA: Lower extremity amputation in people with diabetes: epidemiology and prevention. .Diabetes Care 12::24. ,1989. .
-
8
Gibbons GW, Marcaccio EJ, Habershaw GM: “Management of the Diabetic Foot,” in Vascular Surgery: Theory and Practice, ed by AD Callow, CBN Ernst, p 167, Appleton & Lange, Stamford, CT. ,1995. .
-
9
Pham T, Rich J, Veves A: Wound healing in diabetic foot ulceration: a review and commentary. .Wounds 12::79. ,2002. .
-
10
Reiber GE, Smith DG, Wallace C, et al: Effect of therapeutic footwear on foot reulceration in patients with diabetes: a randomized controlled trial. .JAMA 287::2552. ,2002. .
-
11
Kochman AB, Carnegie DH, Burke TJ: Symptomatic reversal of peripheral neuropathy in patients with diabetes. .JAPMA 92::125. ,2002. .
-
12
Leonard DR, Farooqi MH, Myers S: Restoration of sensation, reduced pain, and improved balance in subjects with diabetic peripheral neuropathy. .Diabetes Care 27::168. ,2004. .
-
13
Prendergast JJ, Miranda G, Sanchez M: Reduced sensory impairment in patients with peripheral neuropathy. .Endocr Pract 10::24. ,2004. .
-
14
Burke TJ: Questions—and answers—about MIRE treatment. .Adv Skin Wound Care 16::369. ,2003. .
-
15
Feet Can Last a Lifetime. Available at: http://www.ndep.nih.gov/diabetes/pubs/Feet_HCGuide.pdf. Accessed April 8. ,2004. .
-
16
Sekuler R, Nash D, Armstrong R: Sensitive, objective procedure for evaluating response to light touch. .Neurology 23::1282. ,1973. .
-
17
Dellon AL: Preventing foot ulceration and amputation by decompressing peripheral nerves in patients with diabetic neuropathy. .Ostomy Wound Manage 48::36. ,2002. .
-
18
Sima AA, Laudio C: Design of controlled clinical trials for diabetic peripheral polyneuropathy. .Semin Neurol 16::187. ,1996. .
-
19
Mayfield JA, Sugarman JR: The use of the Semmes-Weinstein monofilament and other threshold tests for preventing foot ulceration and amputation in persons with diabetes. .J Fam Pract 49::S17. ,2000. .
-
20
Perkins BA, Olaleye D, Zinman B, et al: Simple screening tests for peripheral neuropathy in the diabetes clinic. .Diabetes Care 24::250. ,2001. .
Improved Sensitivity in Patients with Peripheral Neuropathy
Effects of Monochromatic Infrared Photo Energy
Search for other papers by Salvatore L. DeLellis in
Current site
Google Scholar
PubMed
Search for other papers by Dale H. Carnegie in
Current site
Google Scholar
PubMed
Search for other papers by Thomas J. Burke in
Current site
Google Scholar
PubMed
The medical records of 1,047 patients (mean age, 73 years) with established peripheral neuropathy were examined to determine whether treatment with monochromatic infrared photo energy was associated with increased foot sensitivity to the 5.07 Semmes-Weinstein monofilament. The peripheral neuropathy in 790 of these patients (75%) was due to diabetes mellitus. Before treatment with monochromatic infrared photo energy, of the ten tested sites (five on each foot), a mean ± SD of 7.9 ± 2.4 sites were insensitive to the 5.07 Semmes-Weinstein monofilament, and 1,033 patients exhibited loss of protective sensation. After treatment, the mean ± SD number of insensate sites on both feet was 2.3 ± 2.4, an improvement of 71%. Only 453 of 1,033 patients (43.9%) continued to have loss of protective sensation after treatment. Therefore, monochromatic infrared photo energy treatment seems to be associated with significant clinical improvement in foot sensation in patients, primarily Medicare aged, with peripheral neuropathy. Because insensitivity to the 5.07 Semmes-Weinstein monofilament has been reported to be a major risk factor for diabetic foot wounds, the use of monochromatic infrared photo energy may be associated with a reduced incidence of diabetic foot wounds and amputations. (J Am Podiatr Med Assoc 95(2): 143–147, 2005)
advertising
advertising
